Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
Healthcare
$3.14 -0.26%
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
52W Low $3.28High $9.82
Volume 0.10M
Average 0.08M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$17.63M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$1.45M
FY 2025 · Annual
-96.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.08M) | (24.49M) | (67M) | (76.58M) | (17.89M) |
| Depreciation & Amortization | 472K | 718K | 836K | 1.27M | 429K |
| Deferred Income Tax | 66K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.05M | 4.99M | 14.38M | 7.16M | 3.32M |
| Change in Working Capital | (535K) | (1.8M) | 9.86M | 2.03M | (6.25M) |
| Accounts Receivables | 0 | (487K) | (3.93M) | 4.34M | (5.32M) |
| Inventory | 0 | 487K | 0 | 0 | 0 |
| Accounts Payables | 497K | (338K) | 2.2M | (568K) | 176K |
| Other Working Capital | (1.03M) | (1.46M) | 11.59M | (1.74M) | (1.11M) |
| Other Non-Cash Items | 1.44M | 1.93M | 3.35M | 5.19M | 2.76M |
| Operating Cash Flow | (27.58M) | (18.65M) | (38.58M) | (60.93M) | (17.63M) |
| Capital Expenditures | (883K) | (302K) | (362K) | (27K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (68.91M) | (4.49M) | 0 | 0 | 0 |
| Sales of Investments | 69M | 59.01M | 0 | 0 | 0 |
| Other Investing Activities | (201K) | (180K) | 0 | 8K | 0 |
| Investing Cash Flow | (998K) | 54.04M | (362K) | (19K) | 0 |
| Debt Repayment | 4.97M | (43.75M) | 44.08M | (2.06M) | (48.2M) |
| Common Stock Issued | 28.12M | 26.9M | 30.3M | 39.64M | 50.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 558K | (17K) | (169K) | 155K | (420K) |
| Financing Cash Flow | 33.65M | (16.87M) | 74.21M | 37.73M | 1.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 5.07M | 18.52M | 35.27M | (23.22M) | (16.18M) |
| Free Cash Flow | (28.47M) | (18.95M) | (38.94M) | (60.95M) | (17.63M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$17.9M
+ D&A$429.0K
+ Stock-Based Comp$3.3M
+ Deferred Tax$0
- Working Capital-$6.3M
+ Other Non-Cash$2.8M
= Operating Cash Flow-$17.6M
- Capex$0
= Free Cash Flow-$17.6M
Analysis
FY2025 free cash flow is -$17.6M. FCF conversion is 98.6% of net income. Operating cash flow was -$17.6M, with capex of $0. The largest bridge item is Working Capital at -$6.3M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 18, 2026 |
Does VRCA generate free cash flow?
Verrica Pharmaceuticals Inc. (VRCA) generated -$17.63M of free cash flow in fiscal 2025.
How much operating cash flow does VRCA produce?
Operating cash flow was -$17.63M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.